FDA Approves New “Low T” Treatment, Despite Heart Attack Risks

by | March 12th, 2014

All medications available to patients in the United States must undergo a rigorous testing and approval process to ensure they’re safe to use; however, medications are sometimes approved that are later determined to be harmful to patients’ health.

The Ohio Drug Injury Lawyers with Nurenberg, Paris, Heller & McCarthy explain such medications include those that are used to treat low testosterone levels in men. Experts say studies have shown these “Low T” medications can double the risk of heart attack, stroke, pulmonary embolism, and deep venous thrombosis (DVT) in patients age 65 or older, and patients under 65 who have a history of heart disease.

Despite these risks, an article from WebMD stated the U.S. Food and Drug Administration (FDA) recently approved a newer and stronger form of the drug. Patients using the new drug, called Aveed, need only take the medication once every 10 weeks, as opposed to other forms of low testosterone treatment that require a patient take the drug every week or two.

The FDA contends the medications carry warnings about adverse cardiovascular events and that the benefits of the treatment outweigh the Low T Heart Attack Risks patients face.

The attorneys with Nurenberg, Paris, Heller & McCarthy recognize drug manufacturers should be held responsible for the harm their products cause and are here to help anyone who has been injured as the result of taking a medication that was prescribed by a doctor.